{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-243745","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2022-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.153396+00:00","generated_at":"2026-06-23T09:56:01.890538+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"Vaccinex presents neoadjuvant pepinemab combo data at ESMO; triple therapy shows 62.5% pCR in Stage III melanoma","bullets":["Triple combination (nivolumab/ipilimumab/pepinemab) achieved 62.5% pathologic complete response (pCR) and 75% major pathologic response.","Doublet pepinemab/nivolumab showed 25% pCR; pepinemab/ipilimumab 12.5% pCR; nivolumab alone 28.5% pCR.","Triple combination demonstrated significantly improved recurrence-free survival vs doublets (logrank p=0.0097).","All patients underwent surgery without delay; Grade 3 AEs were manageable (5/8 in triple arm).","Correlative biomarker data to be presented at 2022 SITC; further studies needed to confirm durability."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-243745","json":"https://secwatch.observer/filing/0001193125-22-243745.json","markdown":"https://secwatch.observer/filing/0001193125-22-243745.md","text":"https://secwatch.observer/filing/0001193125-22-243745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312522243745/0001193125-22-243745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312522243745/d402023d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:56:01.890538+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}